Drug intelligence / Profile preview

myricetin

Development stage
Preclinical
Lead developer
Impact BioMedical
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral
01

Overview

Myricetin is a naturally occurring flavonoid belonging to the flavonol class of polyphenolic compounds. It is widely found in various plants, including medicinal herbs, vegetables, berries, and tea leaves[1][5][7]. Myricetin exhibits diverse biological activities such as antioxidant, anticancer, antidiabetic, anti-inflammatory, and immunomodulatory effects[2][3][4]. Mechanistically, it acts as a potent free radical scavenger at low concentrations but can display pro-oxidant effects at higher doses[2]. Myricetin has been shown to inhibit angiogenesis by downregulating VEGF secretion via the Akt/p70S6K/HIF-1α pathway and induce apoptosis in cancer cells through mitochondrial pathways[3][8]. In neurological models (e.g., multiple sclerosis), it promotes Nrf2-mediated antioxidative signaling and supports myelination[5]. Recent studies indicate that myricetin inhibits human Uba1 (ubiquitin-like modifier activating enzyme 1) by binding to its ATP-binding site and blocking ubiquitin transfer—suggesting potential for cancer therapy targeting protein ubiquitination pathways[6].

Other names
3,3',4',5,5',7-hexahydroxyflavone
02

Targets

CYP2C8 (Cytochrome P450 2C8)PDIA6 (Protein disulfide-isomerase A6)PDIA3 (Membrane-associated rapid response steroid-binding receptor)OATP (Organic anion transporting polypeptides)P4HB (Protein disulfide-isomerase)UGT1A9 (UDP-glucuronosyltransferase 1A9)UGT2B7 (UDP-glucuronosyltransferase 2B7)UBA1

Beyond the preview

Go deeper on myricetin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on myricetin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call